Navigation Links
European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends
Date:12/21/2010

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan's Tysabri. Prescribing of both Tysabri and Novartis's recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer's Betaferon suffering the most in terms of market share loss. Despite these expected changes, neurologists clearly associate most of the DMAs with a certain MS patient type and their reported prescribing reflects these preference patterns.

The recently released TreatmentTrends®: Multiple Sclerosis in the European Union report finds that neurologists in the U.K. have less clinical experience with many of the DMAs, prescribe DMAs to a smaller percentage of their MS patients, and are detailed less than their counterparts in France, Germany, Italy and Spain. In line with these regional differences, neurologists in the U.K. report relying on different attributes when making their DMA prescribing decisions and identify different unmet needs for DMAs in development compared to neurologists from the other EU regions.

Among the eight therapies in development that were profiled in the research, interest is rated highest for Novartis's Gilenya and Merck Serono's Movectro -- despite the recent nonapproval by the European Medicines Agency for the latter product which Merck has recently appealed. Neurologists in the U.K. again diverge in their reported interest in the DMAs in development with a greater level of enthusiasm for Genzyme/Bayer's alemtuzumab compared to their counterparts in the other EU regions. While familiarity and interest is currently low for Biogen's PEG-Avonex and BG-12, Teva's laquinimod, Sanofi-Aventis's teriflunomide and Abbott/Biogen's daclizumab, for some of these DMAs in development, neurologists appear to have already identified which established DMAs are most at risk with the introduction of these new agents. Knowledge of symptomatic products in development is low with Bayer/Almirall's Sativex and Biogen's Ampyra receiving the highest marks for familiarity, interest and clinical value.

TreatmentTrends®: Multiple Sclerosis in the European Union is a syndicated annual report that provides a comprehensive view of the current and expected future management of MS based on primary research fielded with 229 neurologists in the U.K., France, Germany, Italy and Spain. These reports cover the use of DMAs for the treatment of MS, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use. In addition, respondents were queried about their awareness of and interest in MS-related DMA and symptomatic products in development. A parallel report covering the U.S. market was published in late November.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc. Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com

ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... , 8. Dezember 2016 Mederi Therapeutics Inc . hat die ... nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in China ... ... Live Stretta procedure performed ... Liu, Director of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... Students attending Envision’s summer 2017 ... get hands-on experience in an emergency medical simulation, When Care is Hours Away. ... real-life medical skills that are critical success in a future career and beyond. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... wrinkles and deep lines by smoothing and tightening the skin of the face ... there to address facial aging with very little downtime, Silhouette Instalift is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... ... In the early morning of October 30, Newton County Sheriff’s Deputy Justin ... control of his patrol car. The vehicle overturned into an embankment, causing White to ... Medical Center, where he later succumbed to his injuries. Justin White leaves behind his ...
Breaking Medicine News(10 mins):